Nello Mainolfi - Nov 3, 2023 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Role
Chief Executive Officer, Director
Signature
/s/ Bruce N. Jacobs, as Attorney-in-Fact
Stock symbol
KYMR
Transactions as of
Nov 3, 2023
Transactions value $
$41,600
Form type
4
Date filed
11/6/2023, 06:00 PM
Previous filing
Aug 8, 2023
Next filing
Jan 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KYMR Common Stock Options Exercise $4.93K +2.37K +0.4% $2.08* 589K Nov 3, 2023 Direct
transaction KYMR Common Stock Options Exercise $36.7K +17.6K +2.99% $2.08* 607K Nov 3, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KYMR Stock Option (Right to Buy) Options Exercise $0 -2.37K -100% $0.00* 0 Nov 3, 2023 Common Stock 2.37K $2.08 Direct F1
transaction KYMR Stock Option (Right to Buy) Options Exercise $0 -17.6K -3.23% $0.00 529K Nov 3, 2023 Common Stock 17.6K $2.08 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of February 7, 2019, subject to the reporting person's continued employment through each vesting date.
F2 The shares underlying this stock option vest in forty-eight (48) equal monthly installments following the vesting commencement date of November 14, 2019, subject to the reporting person's continued employment through each vesting date.